Clinical trial
A Phase IIa, Open-Label, 2-Arm Multicenter Clinical Trial to Evaluate the Efficacy, Safety and PK/PD of the Human Anti-CD38 Antibody MOR202 in Anti-PLA2R Antibody Positive Membranous Nephropathy (NewPLACE)
NCT04733040 is registered in ClinicalTrials.gov with HI-Bio, A Biogen Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase IIa, Open-Label, 2-Arm Multicenter Clinical Trial to Evaluate the Efficacy, Safety and PK/PD of the Human Anti-CD38 Antibody MOR202 in Anti-PLA2R Antibody Positive Membranous Nephropathy (NewPLACE)
- Lead sponsor
- HI-Bio, A Biogen Company
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- January 20, 2021
- Completion date
- December 14, 2023
- Enrollment
- 24 (actual)
- Sites
- 25
Conditions
As the registry lists them; a condition with its own page is linked.
antipla2r positive, glomerulonephritis, membranous nephropathy